Increased incidence of symptomatic peripheral neuropathy among adults receiving stavudine- versus zidovudine-based antiretroviral regimens in Kenya

[1]  M. Proschan,et al.  Lactic Acidosis and Symptomatic Hyperlactataemia in a Randomized Trial of First-Line Therapy in HIV-Infected Adults in South Africa , 2011, Antiviral therapy.

[2]  P. Price,et al.  HIV neuropathy risk factors and symptom characterization in stavudine-exposed South Africans. , 2011, Journal of pain and symptom management.

[3]  M. Kamya,et al.  Stavudine Toxicity in Women is the Main Reason for Treatment Change in a 3-Year Prospective Cohort of Adult Patients Started on First-Line Antiretroviral Treatment in Uganda , 2011, Journal of acquired immune deficiency syndromes.

[4]  F. Vaida,et al.  Continued high prevalence and adverse clinical impact of human immunodeficiency virus-associated sensory neuropathy in the era of combination antiretroviral therapy: the CHARTER Study. , 2010, Archives of neurology.

[5]  A. Guantai,et al.  Comparative Tolerability And Efficacy Of Stavudine 30 Mg Versus Stavudine 40 Mg In Patients On Combination Antiretroviral Therapy In Kenya , 2010 .

[6]  P. Price,et al.  Age and height predict neuropathy risk in patients with HIV prescribed stavudine , 2009, Neurology.

[7]  Alison L. Drake,et al.  Impact of prior HAART use on clinical outcomes in a large Kenyan HIV treatment program. , 2009, Current HIV research.

[8]  D. Clifford,et al.  Benefits and risks of stavudine therapy for HIV-associated neurologic complications in Uganda , 2009, Neurology.

[9]  E. Delaporte,et al.  Tolerability and effectiveness of first-line regimens combining nevirapine and lamivudine plus zidovudine or stavudine in Cameroon. , 2008, AIDS research and human retroviruses.

[10]  J. Chmiel,et al.  Initiation of Antiretroviral Therapy at CD4 Cell Counts ≥350 Cells/mm3 Does Not Increase Incidence or Risk of Peripheral Neuropathy, Anemia, or Renal Insufficiency , 2008, Journal of acquired immune deficiency syndromes.

[11]  D. Kuritzkes,et al.  Higher-Than-Expected Rates of Lactic Acidosis Among Highly Active Antiretroviral Therapy-Treated Women in Botswana: Preliminary Results from a Large Randomized Clinical Trial , 2007, Journal of acquired immune deficiency syndromes.

[12]  D. Ngare,et al.  Antiretroviral Durability and Tolerability in HIV-Infected Adults Living in Urban Kenya , 2007, Journal of acquired immune deficiency syndromes.

[13]  J. Brooks,et al.  Clinical Toxicity of Highly Active Antiretroviral Therapy in a Home-Based AIDS Care Program in Rural Uganda , 2007, Journal of acquired immune deficiency syndromes.

[14]  Desmond E. Williams,et al.  Peripheral insensate neuropathy--a tall problem for US adults? , 2006, American journal of epidemiology.

[15]  B. Stilwell,et al.  Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach. 2006 revision. , 2006 .

[16]  Phyllis Kanki,et al.  Management of HIV-1 Infection With a Combination of Nevirapine, Stavudine, and Lamivudine: A Preliminary Report on the Nigerian Antiretroviral Program , 2005, Journal of acquired immune deficiency syndromes.

[17]  K. Lichtenstein,et al.  Modification of the incidence of drug-associated symmetrical peripheral neuropathy by host and disease factors in the HIV outpatient study cohort. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[18]  M. Peeters,et al.  Effectiveness and safety of a generic fixed-dose combination of nevirapine, stavudine, and lamivudine in HIV-1-infected adults in Cameroon: open-label multicentre trial , 2004, The Lancet.

[19]  V. Valcour,et al.  Symptomatic distal sensory polyneuropathy in HIV after age 50 , 2004, Neurology.

[20]  P. Harrigan,et al.  Changes in mitochondrial DNA as a marker of nucleoside toxicity in HIV-infected patients. , 2002, The New England journal of medicine.

[21]  P. Shalit,et al.  Stavudine-associated peripheral neuropathy in zidovudine-naïve patients: Effect of stavudine exposure and antiretroviral experience , 2002, Advances in therapy.

[22]  M. Dalakas.  Peripheral neuropathy and antiretroviral drugs , 2001, Journal of the peripheral nervous system : JPNS.

[23]  J. Smeitink,et al.  Adverse effects of reverse transcriptase inhibitors: mitochondrial toxicity as common pathway , 1998, AIDS.

[24]  M. Tagliati,et al.  Nucleoside analogue-associated peripheral neuropathy in human immunodeficiency virus infection. , 1995, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.